Literature DB >> 15654123

High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins.

Matthias Schneider1, Joseph L Witztum, Stephen G Young, Erwin H Ludwig, Elizabeth R Miller, Sotirios Tsimikas, Linda K Curtiss, Santica M Marcovina, John M Taylor, Richard M Lawn, Thomas L Innerarity, Robert E Pitas.   

Abstract

Efforts to elucidate the role of lipoprotein [a] (Lp[a]) in atherogenesis have been hampered by the lack of an animal model with high plasma Lp[a] levels. We produced two lines of transgenic mice expressing apolipoprotein [a] (apo[a]) in the liver and crossed them with mice expressing human apolipoprotein B-100 (apoB-100), generating two lines of Lp[a] mice. One had Lp[a] levels of approximately 700 mg/dl, well above the 30 mg/dl threshold associated with increased risk of atherosclerosis in humans; the other had levels of approximately 35 mg/dl. Most of the LDL in mice with high-level apo[a] expression was covalently bound to apo[a], but most of the LDL in the low-expressing line was free. Using an enzyme-linked sandwich assay with monoclonal antibody EO6, we found high levels of oxidized phospholipids in Lp[a] from high-expressing mice but not in LDL from low-expressing mice or in LDL from human apoB-100 transgenic mice (P <0.00001), even though all mice had similar plasma levels of human apoB-100. The increase in oxidized lipids specific to Lp[a] in high-level apo[a]-expressing mice suggests a mechanism by which increased circulating levels of Lp[a] could contribute to atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15654123     DOI: 10.1194/jlr.M400467-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  24 in total

1.  Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids.

Authors:  Calvin Yeang; Devin Hasanally; Xuchu Que; Ming-Yow Hung; Aleksandra Stamenkovic; David Chan; Rakesh Chaudhary; Victoria Margulets; Andrea L Edel; Masahiko Hoshijima; Yusu Gu; William Bradford; Nancy Dalton; Phuong Miu; David Yc Cheung; Davinder S Jassal; Grant N Pierce; Kirk L Peterson; Lorrie A Kirshenbaum; Joseph L Witztum; Sotirios Tsimikas; Amir Ravandi
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

2.  Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a).

Authors:  Ayelet Gonen; Xiaohong Yang; Calvin Yeang; Elena Alekseeva; Marlys Koschinsky; Joseph L Witztum; Michael Boffa; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2020-07-08       Impact factor: 5.922

Review 3.  NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Authors:  Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu
Journal:  J Am Coll Cardiol       Date:  2018-01-16       Impact factor: 24.094

4.  Lipoprotein(a) accelerates atherosclerosis in uremic mice.

Authors:  Tanja X Pedersen; Sally P McCormick; Sotirios Tsimikas; Susanne Bro; Lars B Nielsen
Journal:  J Lipid Res       Date:  2010-06-28       Impact factor: 5.922

5.  Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

Authors:  Gregor Leibundgut; Corey Scipione; Huiyong Yin; Matthias Schneider; Michael B Boffa; Simone Green; Xiaohong Yang; Edward Dennis; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

Review 6.  Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.

Authors:  Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

7.  Alternative splicing attenuates transgenic expression directed by the apolipoprotein E promoter-enhancer based expression vector pLIV11.

Authors:  Dongmei Cheng; Philip S MacArthur; Shunxing Rong; John S Parks; Gregory S Shelness
Journal:  J Lipid Res       Date:  2009-10-27       Impact factor: 5.922

Review 8.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

Review 9.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Authors:  Calvin Yeang; Michael J Wilkinson; Sotirios Tsimikas
Journal:  Curr Opin Cardiol       Date:  2016-07       Impact factor: 2.161

10.  PCSK9 Association With Lipoprotein(a).

Authors:  Hagai Tavori; Devon Christian; Jessica Minnier; Deanna Plubell; Michael D Shapiro; Calvin Yeang; Ilaria Giunzioni; Mikael Croyal; P Barton Duell; Gilles Lambert; Sotirios Tsimikas; Sergio Fazio
Journal:  Circ Res       Date:  2016-04-27       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.